Superficial Femoral Artery Stenosis
17
3
6
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.9%
1 terminated out of 17 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (17)
Shockwave IVL + DES
SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries
Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease
SELUTION4SFA Trial
Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)
STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femoro-Popliteal Lesions
VFI in Healthy Vessels
Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
Full Metall Jacket Multilevel Segment
LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries
CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")
Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion
Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)
Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions